Vnitr Lek 2015, 61(9):758-759

Cílená léčba chronické myeloidní leukemie u starších pacientů - editorial

Edgar Faber
Hemato-onklogická klinika LF UP a FN Olomouc, přednosta prof. MUDr. Tomáš Papajík, CSc.

Received: August 10, 2015; Published: September 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Faber E. Cílená léčba chronické myeloidní leukemie u starších pacientů - editorial. Vnitr Lek. 2015;61(9):758-759.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Rohrbacher M, Berger U, Hochhaus A et al. Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leukemia 2009; 23(3): 602-604. Go to original source... Go to PubMed...
    2. Sokal JE, Cox EB, Baccarani M et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 1984; 63(4): 789-799. Go to original source...
    3. Hasford J, Pfirrmann M, Hehlmann R et al. A new prognostic score for the survival of patients with chronic myeloid leukemia. J Natl Cancer Inst 1998; 90(11): 850-858. Go to original source... Go to PubMed...
    4. Faber E, Mužík J, Koza V et al. Treatment of consecutive patients with chronic myeloid leukemia in the cooperating centers from the Czech Republic and the whole Slovakia after 2000 - a report from the CAMELIA Registry. Eur J Haematol 2011; 87(2): 157-168. Go to original source... Go to PubMed...
    5. Björkholm M, Ohm L, Eloranta S et al. Success story of targeted therapy in chronic): myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol 2011; 29(18): 2514-2520. Go to original source... Go to PubMed...
    6. Brenner H, Gondos A, Pulte D. Recent trends in long-term survival of patients with chronic myelocytic leukemia: disclosing the impact of advances in therapy on the population level. Haematologica 2008; 93(10): 1544-1549. Go to original source... Go to PubMed...
    7. Cortes J, Talpaz M, O'Brien S et al. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 2003; 98(6): 1105-1113. Go to original source... Go to PubMed...
    8. Rosti G, Iacobucci I, Bassi S et al. Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. Haematologica 2007; 92(1): 101-105. Go to original source... Go to PubMed...
    9. Sheehy OM, Irvine AE, Cuthbert RJ et al. Use of imatinib mesylate in elderly patients in Northern Ireland: evidence of comparable haematological and molecular responses to younger patients. Hematology 2008; 13(3): 133-136. Go to original source... Go to PubMed...
    10. Sanchez-Guijo FM, Duran S, Galende J et al. Evaluation of tolerability and efficacy of imatinib mesylate in elderly patients with chronic phase CML: ELDERGLI study. Leuk Res 2011; 35(9): 1184-1187. Go to original source... Go to PubMed...
    11. Bělohlávková P, Voglová J, Radocha J et al. Má věk nemocných s chronickou myeloidní leukemií při léčbě imatinibem vliv na dosaženou léčebnou odpověď? Vnitř Lék 2015; 61(9): 785-791. Go to PubMed...
    12. Gotta V, Bouchet S, Widmer N et al. Large-scale imatinib dose-concentration-effect study in CML patients under routine care conditions. Leuk Res 2014; 38(7): 764-772. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.